Advances in sepsis therapy (Q35732033)

9 August 2017

1 reference

title

Advances in sepsis therapy (English)

1 reference

9 August 2017

0 references

Thomas Glück

1

1 reference

9 August 2017

Steven M Opal

series ordinal

2

1 reference

9 August 2017

publication date

1 January 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

64

1 reference

9 August 2017

issue

8

1 reference

9 August 2017

page(s)

837-859

1 reference

Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia

9 August 2017

cites work

1 reference

12 December 2020

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group

1 reference

12 December 2020

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock

1 reference

12 December 2020

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

1 reference

12 December 2020

A new endotoxin adsorber: first clinical application.

1 reference

12 December 2020

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

12 December 2020

Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia

1 reference

12 December 2020

Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients

1 reference

12 December 2020

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

1 reference

12 December 2020

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

1 reference

12 December 2020

Evaluation of CD14 in host defence

1 reference

12 December 2020

Parameters influencing membrane CD14 expression and soluble CD14 levels in sepsis

1 reference

12 December 2020

Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study

1 reference

12 December 2020

Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon

1 reference

12 December 2020

Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions

1 reference

12 December 2020

Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J5 study Group

1 reference

12 December 2020

Treatment of Gram-Negative Septic Shock with Human IgG Antibody to Escherichia coli J5: A Prospective, Double-Blind, Randomized Trial

1 reference

12 December 2020

Is Fas ligand or endotoxin responsible for mucosal lymphocyte apoptosis in sepsis?

1 reference

12 December 2020

Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins

1 reference

12 December 2020

Therapeutic apheresis for septic patients with organ dysfunction: hemoperfusion using a polymyxin B immobilized column

1 reference

12 December 2020

Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice

1 reference

12 December 2020

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis

1 reference

12 December 2020

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

1 reference

12 December 2020

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

1 reference

12 December 2020

Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis

1 reference

12 December 2020

Low-dose heparin for severe sepsis

1 reference

12 December 2020

Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide)

1 reference

12 December 2020

Risks and benefits of activated protein C treatment for severe sepsis

1 reference

12 December 2020

Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis

1 reference

12 December 2020

Anti-inflammatory therapies to treat sepsis and septic shock

1 reference

12 December 2020

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group

1 reference

12 December 2020

Disseminated intravascular coagulation

1 reference

12 December 2020

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

1 reference

12 December 2020

E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators

1 reference

12 December 2020

Effect of CD14 blockade in rabbits with Escherichia coli pneumonia and sepsis

1 reference

12 December 2020

Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.

1 reference

12 December 2020

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

1 reference

12 December 2020

Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia

1 reference

12 December 2020

Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein

1 reference

12 December 2020

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

1 reference

12 December 2020

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

1 reference

12 December 2020

Antibodies against CD14 protect primates from endotoxin-induced shock

1 reference

12 December 2020

Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock

1 reference

12 December 2020

Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia

1 reference

12 December 2020

Increased Circulating Soluble Cd14 Is Associated With High Mortality In Gram-Negative Septic Shock

1 reference

12 December 2020

A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group

1 reference

12 December 2020

Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials

1 reference

12 December 2020

Effect of anti-CD14 monoclonal antibody on clearance of Escherichia coli bacteremia and endotoxemia

1 reference

12 December 2020

Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network

1 reference

12 December 2020

Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis

1 reference

12 December 2020

Why have new effective therapies for sepsis not been developed?

1 reference

12 December 2020

Looking back on HA-1A

1 reference

12 December 2020

Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group.

1 reference

12 December 2020

Tissue factor pathway of coagulation in sepsis

1 reference

12 December 2020

Endotoxemia in human septic shock

1 reference

12 December 2020

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group

1 reference

12 December 2020

Hemofiltration-absorption systems for the treatment of experimental sepsis: is it possible to remove the "evil humors" responsible for septic shock?

1 reference

12 December 2020

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial

1 reference

12 December 2020

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

12 December 2020

CD14 is a pattern recognition receptor

1 reference

12 December 2020

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

1 reference

12 December 2020

The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone

1 reference

12 December 2020

Efficacy and safety of recombinant human activated protein C for severe sepsis

1 reference

12 December 2020

In vivo protection against endotoxin by plasma high density lipoprotein

1 reference

12 December 2020

Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli

1 reference

12 December 2020

Bacterial lipopolysaccharide can enter monocytes via two CD14-dependent pathways.

1 reference

12 December 2020

Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature.

1 reference

12 December 2020

Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies

1 reference

12 December 2020

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

1 reference

12 December 2020

CDP571, a humanized antibody to human tumor necrosis factor-alpha

1 reference

12 December 2020

Intensive insulin therapy in critically ill patients

1 reference

12 December 2020

CD14 plays no major role in shock induced by Staphylococcus aureus but down-regulates TNF-alpha production

1 reference

12 December 2020

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

12 December 2020

Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB.

1 reference

12 December 2020

Anti-endotoxin therapeutic options for the treatment of sepsis

1 reference

12 December 2020

Monoclonal antibodies to tumor necrosis factor in sepsis: help or harm?

1 reference

12 December 2020

p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group

1 reference

12 December 2020

Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned

1 reference

12 December 2020

Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial

1 reference

12 December 2020

Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group

1 reference

12 December 2020

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

1 reference

12 December 2020

IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans

1 reference

12 December 2020

Early goal-directed therapy in the treatment of severe sepsis and septic shock

1 reference

12 December 2020

A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group

1 reference

12 December 2020

Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study

1 reference

12 December 2020

Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection

1 reference

12 December 2020

Different efficacy of soluble CD14 treatment in high- and low-dose LPS models

1 reference

12 December 2020

Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases

1 reference

12 December 2020

1 reference

12 December 2020

Bench-to-bedside review: Toll-like receptors and their role in septic shock

1 reference

12 December 2020

Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts

1 reference

12 December 2020

Epidemiology of sepsis: an update

1 reference

12 December 2020

An economic evaluation of activated protein C treatment for severe sepsis

1 reference

12 December 2020

LPS-binding proteins and receptors

1 reference

12 December 2020

Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications

1 reference

12 December 2020

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis

1 reference

12 December 2020

Time course of hemostatic abnormalities in sepsis and its relation to outcome.

1 reference

12 December 2020

Immune depression in polymicrobial sepsis: The role of necrotic (injured) tissue and endotoxin

1 reference

12 December 2020

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.

1 reference

12 December 2020

The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage

1 reference

12 December 2020

Human albumin administration in critically ill patients: systematic review of randomised controlled trials

1 reference

12 December 2020

Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis

1 reference

12 December 2020

Endotoxin as a drug target

1 reference

12 December 2020

Reversal of late septic shock with supraphysiologic doses of hydrocortisone

1 reference

12 December 2020

Assessing the use of activated protein C in the treatment of severe sepsis

1 reference

12 December 2020

Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability-increasing protein and cefamandole in treatment of rabbit gram-negative sepsis.

1 reference

12 December 2020

Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5.

1 reference

12 December 2020

Removal of pro-inflammatory cytokines with renal replacement therapy: sense or nonsense?

1 reference

12 December 2020

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

1 reference

12 December 2020

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

1 reference

12 December 2020

Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery

1 reference

12 December 2020

Optimizing antibiotic therapy in the intensive care unit setting

1 reference

12 December 2020

Endothelial cell dysfunction and coagulation

1 reference

12 December 2020

Failure of prophylactic and therapeutic use of a murine anti-tumor necrosis factor monoclonal antibody in Escherichia coli sepsis in the rabbit

1 reference

12 December 2020

CD14, new aspects of ligand and signal diversity

1 reference

12 December 2020

Antithrombin, heparin, and heparan sulfate

1 reference

12 December 2020

Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group

1 reference

12 December 2020

The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis

1 reference

12 December 2020

The biology of Toll-like receptors

1 reference

12 December 2020

Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome

1 reference

12 December 2020

Why immunomodulatory therapies have not worked in sepsis

1 reference

12 December 2020

Antithrombin III in animal models of sepsis and organ failure

1 reference

12 December 2020

Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group

1 reference

12 December 2020

The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin

1 reference

12 December 2020

Shock and tissue injury induced by recombinant human cachectin

1 reference

12 December 2020

Bacterial endotoxin: molecular relationships of structure to activity and function

1 reference

12 December 2020

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

1 reference

12 December 2020

Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial

1 reference

12 December 2020

Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study.

1 reference

12 December 2020

Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study

1 reference

12 December 2020

Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88.

1 reference

12 December 2020

Coagulation in severe sepsis: a central role for thrombomodulin and activated protein C.

1 reference

12 December 2020

Endotoxin, tumor necrosis factor, and related mediators: new approaches to shock.

1 reference

12 December 2020

10.2165/00003495-200464080-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

9 August 2017

1006997650

0 references

1 reference